HIV therapeutic vaccines aimed at intensifying combination antiretroviral therapy

References

• UNAIDS. 2018. Available from: http://www.unaids.org/en/resources/documents/2018/unaids-data-2018
   Google Scholar
• Siliciano JM, Siliciano RF. The remarkable stability of the latent reservoir for HIV-1 in resting memory CD4+ T cells. J Infect Dis. 2015;212:1345–1347.
   PubMed Web of Science ®Google Scholar
• Gupta RK, Jordan MR, Sultan BJ, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet. 2012;380:1250–1258.
   PubMed Web of Science ®Google Scholar
• Kelley CF, Kitchen CMR, Hunt PW, et al. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis. 2009;48:787–794.
   PubMed Web of Science ®Google Scholar
• Keiser O, Anastos K, Schechter M, et al. Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health. 2008;13:870–879.
   PubMed Web of Science ®Google Scholar
• Abrams D, Lévy Y, Losso MH, et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med. 2009;361:1548–1559.
   PubMed Web of Science ®Google Scholar
• Hatano H, Hayes TL, Dahl V, et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T-cell response. J Infect Dis. 2011;203:960–968.
   PubMed Web of Science ®Google Scholar
• Stephenson KE. Therapeutic vaccination for HIV: hopes and challenges. Curr Opin HIV AIDS. 2018;13:408–415.
   PubMed Web of Science ®Google Scholar
• Mylvaganam GH, Silvestri G, Amara RR. HIV therapeutic vaccines: moving towards a functional cure. Curr Opin Immunol. 2015;35:1–8.
   PubMed Web of Science ®Google Scholar
• Betts MR, Nason MC, West SM, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood. 2006;107:4781–4789.
   PubMed Web of Science ®Google Scholar
• Deng K, Pertea M, Rongvaux A, et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature. 2015;517:381–385.
   PubMed Web of Science ®Google Scholar
• Perreau M, Savoye AL, De Crignis E, et al. Follicular helper T cells serve as the major CD4+ T cell compartment for HIV-1 infection, replication, and production. J Exp Med. 2013;210:143–156.
   PubMed Web of Science ®Google Scholar
• Schieffer M, Jessen HK, Oster AF. Induction of Gag-specific CD4+ T cell responses during acute HIV infection is associated with improved viral control. J Virol. 2014;88:7357–7366.
   PubMed Web of Science ®Google Scholar
• Garcia F, Leon A, Gatell JM, et al. Therapeutic vaccines against HIV infection. Hum Vaccin Immunother. 2012;8:569–581.
   PubMed Web of Science ®Google Scholar
• Ensoli B, Cafaro A, Monini P, et al. Challenges in HIV vaccine research for treatment and prevention. Front Immunol. 2014;5:417.
   PubMed Web of Science ®Google Scholar
• Saksena NK, Potter SJ. Reservoirs of HIV-1 in vivo: implications for antiretroviral therapy. AIDS Rev. 2003;5:3–18.
   PubMedGoogle Scholar
• Carcelain G, Autran B. Immune interventions in HIV infection. Immunol Rev. 2013;254:355–371.
   PubMed Web of Science ®Google Scholar
• Vanham G, Van GE. Can immunotherapy be useful as a “functional cure” for infection with human immunodeficiency virus-1? Retrovirology. 2012;9:72.
   PubMed Web of Science ®Google Scholar
• Autran B. Toward a cure for HIV-seeking effective therapeutic vaccine strategies. Eur J Immunol. 2015;45:3215–3221.
   PubMed Web of Science ®Google Scholar
• Leal L, Lucero C, Gatell JM, et al. New challenges in therapeutic vaccines against HIV infection. Expert Rev Vaccines. 2017;16:587–600.
   PubMed Web of Science ®Google Scholar
• Pollard C, De Koker S, Saelens X, et al. Challenges and advances towards the rational design of mRNA vaccines. Trends Mol Med. 2013;19:705–713.
   PubMed Web of Science ®Google Scholar
• Pantaleo G, Levy Y. Therapeutic vaccines and immunological intervention in HIV infection: a paradigm change. Curr Opin HIV AIDS. 2016;11:576–584.
   PubMed Web of Science ®Google Scholar
• Barouch DH, Deeks SG. Immunologic strategies for HIV-1 remission and eradication. Science. 2014;345:169–174.
   PubMed Web of Science ®Google Scholar
• Vieillard V, Combadiere B, Tubiana R, et al. HIV therapeutic vaccine enhances non-exhausted CD4+ T cells in a randomised phase 2 trial. Npj Vaccines. 2019;4:25.
   PubMed Web of Science ®Google Scholar
• van Lunzen J, Pantaleo G, Arastéh K, et al. Vacc-4x/lenalidomide increases naïve CD4+ T-cells in well controlled patients on ART with low preART CD4+ counts and poor immune reconstitution.IAS 2015 Towards an HIV Cure Symposium, Vancouver, Canada, Poster Abstract PE61.
   Google Scholar
• Casazza JP, Bowman KA, Adzaku S, et al. Therapeutic vaccination expands and improves the function of the HIV-specifi c memory T-cell repertoire. J Infect Dis. 2013;207:1829–1840.
   PubMed Web of Science ®Google Scholar
• Lisziewicz J, Bakare N, Calarota SA, et al. Single DermaVir immunization: dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individuals. PLoS One. 2012;7:e35416.
   PubMed Web of Science ®Google Scholar
• Rodriguez B, Asmuth DM, Matining RM, et al. Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG5176 trial. J Aids. 2013;64:351–359.
   PubMed Web of Science ®Google Scholar
• Létourneau S, Im E-J, Mashishi T, et al. Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One. 2007;2:e984.
   PubMed Web of Science ®Google Scholar
• Mothe B, Manzardo C, Sanchez-Bernabeu A, et al. Therapeutic vaccination refocuses T-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study). EClinicalMedicine. 2019;11:65–80.
   PubMedGoogle Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245–252.
   PubMed Web of Science ®Google Scholar
• Mothe B, Llano A, Ibarrondo J, et al. Definition of the viral targets of protective HIV-1-specific T cell responses. J Transl Med. 2011;9:208.
   PubMed Web of Science ®Google Scholar
• Leal L, Guardo AC, Moron-Lopez S, et al. Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection. AIDS. 2018;32:2533–2545.
   PubMed Web of Science ®Google Scholar
• Achenbach CJ, Assoumou L, Deeks SG, et al. Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomized clinical trial. Lancet HIV. 2015;2:82–91.
   PubMed Web of Science ®Google Scholar
• Argos Therapeutics website. HIV clinical trials. Available from: http://www.argostherapeutics.com/hiv-clinical-trials/.
   Google Scholar
• Barouch DH, Picker LJ. Novel vaccine vectors for HIV-1. Nat Rev Microbiol. 2017;15:696.
   PubMed Web of Science ®Google Scholar
• Barouch DH, Tomaka FL, Wegmann F, et al. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13–19). Lancet. 2018;392:232–243.
   PubMed Web of Science ®Google Scholar
• Mothe B, Llano A, Ibarrondo J, et al. CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control. PLoS One. 2012;7:e29717.
   PubMed Web of Science ®Google Scholar
• Ondondo B, Murakoshi H, Clutton G, et al. Novel conserved-region T-cell mosaic vaccine with high global HIV-1 coverage is recognized by protective responses in untreated infection. Mol Ther. 2016;24:832–842.
   PubMed Web of Science ®Google Scholar
• Arya SK, Guo C, Josephs SF, et al. Trans-activator gene of human T lymphotropic virus type III [HTLV III]. Science. 1985;229:69–73.
   PubMed Web of Science ®Google Scholar
• Fisher AG, Feinberg MB, Joseph SF, et al. The trans-activator gene of HTLV-III is essential for virus replication. Nature. 1986;320:367–371.
   PubMed Web of Science ®Google Scholar
• Ensoli B, Buonaguro L, Barillari G, et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol. 1993;67:277–287.
   PubMed Web of Science ®Google Scholar
• Chang HC, Samaniego F, Nair BC, et al. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS. 1997;11:1421–1431.
   PubMed Web of Science ®Google Scholar
• Albini A, Ferrini S, Benelli R, et al. HIV-1 Tat protein mimicry of chemokines. Proc Natl Acad Sci USA. 1998;95:13153–13158.
   PubMed Web of Science ®Google Scholar
• Huang L, Bosch I, Hofmann W, et al. Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains. J Virol. 1998;72:8952–8960.
   PubMed Web of Science ®Google Scholar
• Secchiero P, Zella D, Capitani S, et al. Extracellular HIV-1 tat protein upregulates the expression of surface CXC-chemokine receptor 4 in resting CD4+ T cells. J Immunol. 1999;162:2427–2431.
   PubMed Web of Science ®Google Scholar
• Ghezzi S, Noonan DM, Aluigi MG, et al. Inhibition of CXCR4-dependent HIV-1 infection by extracellular HIV-1 Tat. Biochem Biophys Res Commun. 2000;270:992–996.
   PubMed Web of Science ®Google Scholar
• Johnson TP, Patel K, Johnson KR, et al. Induction of IL-17 and nonclassical T-cell activation by HIV-Tat protein. Proc Natl Acad Sci USA. 2013;110:13588–13593.
   PubMed Web of Science ®Google Scholar
• Nappi F, Chiozzini C, Bordignon V, et al. Immobilized HIV-1 Tat protein promotes gene transfer via a transactivation independent mechanism which requires binding of Tat to viral particles. J Gene Med. 2009;11:955–965.
   PubMed Web of Science ®Google Scholar
• Chertova E, Chertov O, Coren LV, et al. Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages. J Virol. 2006;80:9039–9052.
   PubMed Web of Science ®Google Scholar
• Monini P, Cafaro A, Srivastava IK, et al. HIV-1 Tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env Spikes and competes neutralization by Anti-HIV antibodies. PLoS One. 2012;7:e48781. .
   PubMed Web of Science ®Google Scholar
• Poon S, Moscoso CG, Xing L, et al. Putative role of Tat-Env interaction in HIV infection. AIDS. 2013;27:2345–2354.
   PubMed Web of Science ®Google Scholar
• Fanales-Belasio E, Moretti S, Nappi F, et al. Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses. J Immunol. 2002;168:197–206.
   PubMed Web of Science ®Google Scholar
• Gavioli R, Gallerani E, Fortini C, et al. HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity. J Immunol. 2004;173:3838–3843.
   PubMed Web of Science ®Google Scholar
• Fanales-Belasio E, Moretti S, Fiorelli V, et al. HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection. J Immunol. 2009;182:2888–2897.
   PubMed Web of Science ®Google Scholar
• Sforza F, Nicoli F, Gallerani E, et al. HIV-1 Tat affects the programming and functionality of human CD8++ T cells by modulating the expression of T-box transcription factors. AIDS. 2014;28:1729–1738.
   PubMed Web of Science ®Google Scholar
• Chiozzini C, Collacchi B, Nappi F, et al. Surface-bound Tat inhibits antigen-specific CD8++ T cell activation in an integrin-dependent manner. AIDS. 2014;28:2189–2200.
   PubMed Web of Science ®Google Scholar
• Re MC, Vignoli M, Furlini G, et al. Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable VL in HIV-1 seropositive patients. J Clin Virol. 2001;21:81–89.
   PubMed Web of Science ®Google Scholar
• Zagury JF, Sill A, Blattner W, et al. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine. J Hum Virol. 1998;1:282–292.
   PubMedGoogle Scholar
• Rezza G, Fiorelli V, Dorrucci M, et al. The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters. J Infect Dis. 2005;191:1321–1324.
   PubMed Web of Science ®Google Scholar
• Bellino S, Tripiciano A, Picconi O, et al. The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4++ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study. Retrovirology. 2014;11:49.
   PubMed Web of Science ®Google Scholar
• Butto` S, Fiorelli V, Tripiciano A, et al. Sequence conservation and antibody cross-recognition of clade B Human Immunodeficiency Virus (HIV) Type 1 Tat protein in HIV-1–infected Italians, Ugandans, and South Africans. J Infect Dis. 2003;188:1171–1180.
   PubMed Web of Science ®Google Scholar
• Cafaro A, Tripiciano A, Sgadari C, et al. Development of a novel AIDS vaccine: the HIV-1 Tat protein vaccine. Expert Opin Biol Ther. 2015;22:1–17.
   Google Scholar
• Pollack RA, Jones RB, Pertea M, et al. Defective HIV-1 proviruses are expressed and can be recognized by cytotoxic T lymphocytes, which shape the proviral landscape. Cell Host Microbe. 2017;21:494–506.e4.
   PubMed Web of Science ®Google Scholar
• Mediouni S, Darque A, Baillat G, et al. Antiretroviral therapy does not block the secretion of the human immunodeficiency virus tat protein. Infect Disord Drug Targets. 2012;12(1):81–86.
   PubMedGoogle Scholar
• Razooky BS, Pai A, Aull K, et al. HIV latency program. Cell. 2015;160(5):990–1001. .
   PubMed Web of Science ®Google Scholar
• Cafaro A, Caputo A, Fracasso C, et al. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat Med. 1999;5(6):643–650.
   PubMed Web of Science ®Google Scholar
• Cafaro A, Caputo A, Maggiorella MT, et al. SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine. J Med Primatol. 2000;29(3–4):193–208.
   PubMed Web of Science ®Google Scholar
• Cafaro A, Titti F, Fracasso C, et al. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus [SHIV89.6P]. Vaccine. 2001;19(20–22):2862–2877.
   PubMed Web of Science ®Google Scholar
• Cafaro A, Bellino S, Titti F, et al. Impact of viral dose and major histocompatibility complex class IB haplotype on viral outcome in Tat-vaccinated mauritian cynomolgus monkeys upon challenge with SHIV89.6P. J Virol. 2010;84(17):8953–8958.
   PubMed Web of Science ®Google Scholar
• Maggiorella MT, Baroncelli S, Michelini Z, et al. Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. Vaccine. 2004;22(25–26):3258–3269.
   PubMed Web of Science ®Google Scholar
• Borsetti A, Baroncelli S, Maggiorella MT, et al. Viral outcome of simian human immunodeficiency virus SHIV-89.6P adapted to cynomolgus monkeys. Arch Virol. 2008;153(3):463–472.
   PubMed Web of Science ®Google Scholar
• Titti F, Maggiorella MT, Ferrantelli F, et al. Biocompatible anionic polymeric microspheres as priming delivery system for effetive HIV/AIDS Tat-based vaccines. PLoS One. 2014 Oct 30;9(10):e111360. .
   PubMed Web of Science ®Google Scholar
• Bachler BC, Humbert M, Palikuqi B, et al. Novel biopanning strategy to identify protection epitopes associated with vaccine. J Virol. 2013;87(8):4403.
   PubMed Web of Science ®Google Scholar
• Florese RH, Demberg T, Xiao P, et al. Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J Immunol. 2009;182(6):3718–3727.
   PubMed Web of Science ®Google Scholar
• Ensoli B, Fiorelli V, Ensoli F, et al. The therapeutic phase I trial of the recombinant native HIV-1 Tat protein. AIDS. 2008;22:2207–2209.
   PubMed Web of Science ®Google Scholar
• Longo O, Tripiciano A, Fiorelli V, et al. Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up. Vaccine. 2009;27(25–26):3306–3312.
   PubMed Web of Science ®Google Scholar
• Ensoli B, Fiorelli V, Ensoli F, et al. The preventive phase I trial with the HIV-1 Tat based vaccine. Vaccine. 2009;28:371–378.
   PubMed Web of Science ®Google Scholar
• Bellino S, Francavilla V, Longo O, et al. Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate. Rev Recent Clin Trials. 2009;4:195–204.
   PubMedGoogle Scholar
• Ensoli B, Bellino S, Tripiciano A, et al. Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS ONE. 2010;5:e13540. .
   PubMed Web of Science ®Google Scholar
• Ensoli F, Cafaro A, Casabianca A, et al. HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II clinical trial. Retrovirology. 2015;12:33. .
   PubMed Web of Science ®Google Scholar
• Sgadari C, Monini P, Tripiciano A, et al. Continued decay of HIV proviral DNA upon vaccination with HIV-1 Tat of subjects on long-term ART: an 8-year follow-up study. Front Immunol. 2019 13;10:233.
   PubMed Web of Science ®Google Scholar
• Besson GJ, Lalama CM, Bosch RJ, et al. HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy. Clin Infect Dis. 2014;59:1312–1321.
   PubMed Web of Science ®Google Scholar
• Laanani M, Ghosn J, Essat A, et al. Impact of the timing of initiation of antiretroviral therapy during primary HIV-1 infection on the decay of cell-associated HIV-DNA. Clin Infect Dis. 2015;60:1715–1721.
   PubMed Web of Science ®Google Scholar
• Bachmann N, von Siebenthal C, Vongrad V, et al. Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART. Nat Commun. 2019;10:3193.
   PubMed Web of Science ®Google Scholar
• Golob JL, Stern J, Holte S, et al. HIV DNA levels and decay in a cohort of 111 long-term virally suppressed patients. AIDS. 2018;32:2113–2118.
   PubMed Web of Science ®Google Scholar
• Jaafoura S, de Goër de Herve MG, Hernandez-Vargas EA, et al. Progressive contraction of the latent HIV reservoir around a core of less-differentiated CD4++ memory T Cells. Nat Commun. 2014;5:5407.
   PubMed Web of Science ®Google Scholar
• Ensoli B, Nchabeleng M, Ensoli F, et al. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4+ T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial. Retrovirology. 2016;13:34. .
   PubMed Web of Science ®Google Scholar
• Pitman MC, Lau JSY, McMahon JH, et al. Barriers and strategies to achieve a cure for HIV. Lancet HIV. 2018;5:e317–28.
   PubMed Web of Science ®Google Scholar
• Sicurella M, Nicoli F, Gallerani E, et al. An attenuated herpes simplex virus type 1 (HSV1) encoding the HIV-1 Tat protein protects mice from a deadly mucosal HSV1 challenge. PLoS One. 2014;9:e100844.
   PubMed Web of Science ®Google Scholar
• Nicoli F, Gallerani E, Skarlis C, et al. Systemic immunodominant CD8 responses with an effector-like phenotype are induced by intravaginal immunization with attenuated HSV vectors expressing HIV Tat and mediate protection against HSV infection. Vaccine. 2016;34:2216–2224.
   PubMed Web of Science ®Google Scholar
• Dutta A, Barker C, Kallarakal A. The HIV treatment gap: estimates of the financial resources needed versus available for scale-up of antiretroviral therapy in 97 countries from 2015 to 2020. PLoS Med. 2015;12(11):e1001907.
   PubMed Web of Science ®Google Scholar